etamivan etamivan etamivan (inn, or ethamivan (usan); trade names analepticon, emivan, and vandid) is a respiratory stimulant drug related to nikethamide. it was mainly used in the treatment of barbiturate overdose and chronic obstructive pulmonary disease, but has now largely fallen into disuse. etamivanclinical datatrade namesanalepticonatc coder07ab04 (who) identifiers iupac name n,n-diethyl-4-hydroxy-3-methoxybenzamide cas number304-84-7 ypubchem cid9363drugbankdb08989 nchemspider8996 nuniim44o63ypv9keggd04080 ycomptox dashboard (epa)dtxsid3023007 echa infocard100.005.599 chemical and physical dataformulac12h17no3molar mass223.272 g·mol−13d model (jsmol)interactive image smiles ccn(cc)c(=o)c1ccc(o)c(oc)c1 inchi inchi=1s/c12h17no3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14h,4-5h2,1-3h3 nkey:bqjodpimmwwmfc-uhfffaoysa-n n ny (what is this?) (verify) adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. more serious adverse events include muscle twitching, tremors, and convulsions. the dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.